NexgenRx Stock Price, News & Analysis (CVE:NXG) C$0.24 +0.01 (+2.17%) (As of 12/6/2023 05:23 PM ET) Add Compare Share Share Today's RangeC$0.23▼C$0.2450-Day RangeC$0.21▼C$0.2652-Week RangeC$0.21▼C$0.35Volume18,505 shsAverage Volume11,549 shsMarket CapitalizationC$16.57 millionP/E RatioN/ADividend Yield8.51%Price TargetN/A Stock AnalysisStock AnalysisChartEarningsHeadlinesInsider TradesStock AnalysisChartEarningsHeadlinesInsider Trades About NexgenRxNexgenRx Inc. administers, adjudicates, and pays drug, dental, and other extended health-care claims for the beneficiaries of health benefit plans underwritten by its customers in Canada. It offers NexSys claims management; NexAdmin plan administration; and NexPSPAssist patient support programs. NexgenRx Inc. was incorporated in 2003 and is headquartered in Toronto, Canada.Read More NXG Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NXG Stock News HeadlinesOctober 25, 2023 | seekingalpha.comNXG NXG NextGen Infrastructure Income FundAugust 26, 2023 | theglobeandmail.comClosing Bell: Nexgenrx Inc flat on Friday (NXG)December 9, 2023 | DTI Trader (Ad)New CBOE “special perk” helps traders target income every weekendYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. August 25, 2023 | theglobeandmail.comClosing Bell: Nexgenrx Inc down on Thursday (NXG)August 22, 2023 | theglobeandmail.comClosing Bell: Nexgenrx Inc up on Wednesday (NXG)June 16, 2023 | msn.comNexgenRx Inc. declares $0.005 dividendJune 15, 2023 | finanznachrichten.deNexgenRx Inc.: NexgenRx Announces Declaration of DividendMay 19, 2023 | msn.comNexgenRx reports Q1 resultsDecember 9, 2023 | Autonomix (Ad)[Investor Alert] Potential Breakthrough Medical Tech Investment OpportunityAutonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comMay 10, 2023 | theglobeandmail.comClosing Bell: Nexgenrx Inc down on Friday (NXG)May 8, 2023 | ca.finance.yahoo.comNexgenRx Inc. (NXG.V)May 6, 2023 | theglobeandmail.comClosing Bell: Nexgenrx Inc up on Friday (NXG)May 4, 2023 | theglobeandmail.comClosing Bell: Nexgenrx Inc down on Tuesday (NXG)April 21, 2023 | theglobeandmail.comClosing Bell: Nexgenrx Inc flat on Wednesday (NXG)March 6, 2023 | finance.yahoo.comIs NexgenRx Inc.'s (CVE:NXG) Recent Stock Performance Tethered To Its Strong Fundamentals?February 26, 2023 | nasdaq.comNXG NextGen Infrastructure Income Fund Common Shares of Beneficial Interest (NXG)February 20, 2023 | finance.yahoo.com733085 (NXG) Stock Historical Prices & Data - Yahoo FinanceSeptember 26, 2022 | finance.yahoo.comDeclining Stock and Solid Fundamentals: Is The Market Wrong About NexgenRx Inc. (CVE:NXG)?September 23, 2022 | finance.yahoo.comNexgenrx Announces Declaration Of DividendSeptember 12, 2022 | reuters.comNXG.V - NexgenRx Inc. | Stock Price & Latest News | ReutersDecember 21, 2021 | yahoo.comRETIRE ON TRACK: The real magic of investing begins when you start using ratiosOctober 22, 2021 | news.yahoo.comWomen are being jailed for losing their pregnancies. The US’s post-Roe v Wade reality is already hereOctober 19, 2021 | finance.yahoo.comIs NexgenRx Inc.'s (CVE:NXG) Latest Stock Performance Being Led By Its Strong Fundamentals?August 20, 2021 | finance.yahoo.comI Ran A Stock Scan For Earnings Growth And NexgenRx (CVE:NXG) Passed With EaseAugust 20, 2021 | yahoo.com'AGT' results show: Is 9-year-old Victory Brinker moving on to the semifinals?August 18, 2021 | finanznachrichten.deNexgenRx Inc.: NexgenRx Announces Financial Results for Q2 2021 With Continued Growth in Revenues and Adjusted EBITDAAugust 18, 2021 | apnews.comNexgenRx Announces Financial Results for Q2 2021 With Continued Growth in Revenues and Adjusted EBITDASee More Headlines Receive NXG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NexgenRx and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today12/09/2023Next Earnings (Estimated)4/04/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeCVE Industry Healthcare Plans Sub-IndustryN/A SectorMedical Current SymbolCVE:NXG CUSIPN/A CIKN/A Webwww.nexgenrx.com Phone+1-416-6953393FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)C($0.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeC$3.06 million Net Margins-2.27% Pretax MarginN/A Return on Equity-3.49% Return on Assets-0.04% Debt Debt-to-Equity Ratio4.69 Current Ratio1.08 Quick Ratio0.12 Sales & Book Value Annual SalesC$13.65 million Price / Sales1.21 Cash FlowC$0.02 per share Price / Cash Flow9.64 Book ValueC$0.10 per share Price / Book2.35Miscellaneous Outstanding Shares70,530,000Free FloatN/AMarket CapC$16.57 million OptionableNot Optionable Beta0.35 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesMr. Ronald C. Loucks B.B.A. (Age 73)Founder, CEO, President & Director Comp: $286.66kMr. Kelly Elher C.A.CPA, CA, CPA, Chief Financial OfficerMr. Andrew MunroeSenior Vice President of Pharma & Payor PartnersMr. Jason RobinsonSenior Vice President of AdministrationMs. Doreen HarveyLead Human ResourcesMr. Paul Anthony Bolger LL.B.M.B.A., Company SecretaryMr. Avik DebroyFinancial ControllerMore ExecutivesKey CompetitorsBLVD CentersCVE:CXVMedicureCVE:MPHReunion NeuroscienceTSE:REUN48North CannabisCVE:NRTHNeptune Wellness SolutionsTSE:NEPTView All Competitors NXG Stock Analysis - Frequently Asked Questions How have NXG shares performed in 2023? NexgenRx's stock was trading at C$0.27 at the beginning of 2023. Since then, NXG shares have decreased by 11.3% and is now trading at C$0.24. View the best growth stocks for 2023 here. When is NexgenRx's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024. View our NXG earnings forecast. Is NexgenRx a good dividend stock? NexgenRx (CVE:NXG) pays an annual dividend of C$0.02 per share and currently has a dividend yield of 8.00%. NXG has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. What other stocks do shareholders of NexgenRx own? Based on aggregate information from My MarketBeat watchlists, some companies that other NexgenRx investors own include WestJet Airlines (WJA) and Hydro One (H). How do I buy shares of NexgenRx? Shares of NXG stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. This page (CVE:NXG) was last updated on 12/9/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NexgenRx Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.